0 161

Cited 0 times in

An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer

Authors
 Sun Min Lim  ;  Woong Youn Chung  ;  Kee-Hyun Nam  ;  Sang-Wook Kang  ;  Jae Yun Lim  ;  Hoon-Gu Kim  ;  Seong Hoon Shin  ;  Jong-Mu Sun  ;  Seong-Geun Kim  ;  Joo-Hang Kim  ;  Chan Woo Kang  ;  Hye Ryun Kim  ;  Byoung Chul Cho 
Citation
 European Journal of Cancer, Vol.51(12) : 1588-1595, 2015 
Journal Title
 European Journal of Cancer 
ISSN
 0959-8049 
Issue Date
2015
Abstract
BACKGROUND: This phase 2 study investigated the efficacy and safety of dovitinib (TKI258), a receptor tyrosine kinase inhibitor with potent activity against fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR), in locally advanced or metastatic thyroid cancer patients. PATIENTS AND METHODS: Patients with advanced thyroid cancer that was refractory or not appropriate for (131)I received dovitinib orally, 500mg once daily for five consecutive days, followed by a 2-day rest every week. The primary end-point was objective response rate. Secondary end-points were progression-free survival (PFS), overall survival (OS), duration of response, changes in tumour markers and safety. RESULTS: Between January 2013 and October 2014, a total of 40 patients were enrolled. There were 23 (57.5%) papillary thyroid cancer, 12 (30%) medullary thyroid cancer and 5 (12.5%) follicular thyroid cancer patients. One patient had withdrawn consent before the administration of dovitinib. The overall response rate was 20.5% (8/39) and disease control rate was 69.1% (26/39). Median PFS was 5.4 months (95% confidence interval (CI), 2.0-8.8) and median OS was not reached with 8.4 months follow-up duration. Common treatment-related adverse events were diarrhoea (53.8%), anorexia (35.8%), vomiting (25.6%), fatigue (23%) and nausea (20.5%), most of which were grade 1 or 2. There were no grade 4 events or treatment-related deaths. Dose interruption occurred in 12 (30.7%) patients, and 19 (48.7%) patients experienced dose reduction due to adverse events. CONCLUSIONS: Dovitinib has a modest activity with manageable toxicity in locally advanced or metastatic thyroid cancer.
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/140778
DOI
10.1016/j.ejca.2015.05.020
Appears in Collections:
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실)
1. Journal Papers (연구논문) > 1. College of Medicine (의과대학) > Yonsei Biomedical Research Center (연세의생명연구원)
Yonsei Authors
강상욱(Kang, Sang Wook) ; 강찬우(Kang, Chan Woo) ; 김주항(Kim, Joo Hang) ; 김혜련(Kim, Hye Ryun) ; 남기현(Nam, Kee Hyun) ; 임선민(Lim, Sun Min) ; 임재윤(Lim, Jae Yun) ; 정웅윤(Chung, Woung Youn) ; 조병철(Cho, Byoung Chul)
사서에게 알리기
  feedback
Full Text
http://www.sciencedirect.com/science/article/pii/S0959804915004517
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse